Zacks: Brokerages Expect Agios Pharmaceuticals (AGIO) Will Announce Quarterly Sales of $13.59 Million

Analysts predict that Agios Pharmaceuticals (NASDAQ:AGIO) will post $13.59 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Agios Pharmaceuticals’ earnings. The lowest sales estimate is $10.60 million and the highest is $17.00 million. Agios Pharmaceuticals posted sales of $10.51 million in the same quarter last year, which indicates a positive year-over-year growth rate of 29.3%. The business is expected to report its next earnings results before the market opens on Thursday, May 3rd.

On average, analysts expect that Agios Pharmaceuticals will report full-year sales of $111.39 million for the current fiscal year, with estimates ranging from $58.30 million to $215.80 million. For the next year, analysts forecast that the business will report sales of $311.22 million per share, with estimates ranging from $85.66 million to $734.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The business had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $12.65 million. During the same period last year, the company posted ($1.34) earnings per share. The firm’s revenue for the quarter was down 56.7% on a year-over-year basis.



A number of equities analysts have weighed in on the stock. Oppenheimer cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 14th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 price objective for the company in a research report on Tuesday, January 16th. ValuEngine raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub raised shares of Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 3rd. Finally, Royal Bank of Canada upped their price objective on shares of Agios Pharmaceuticals to $91.00 and gave the company an “outperform” rating in a research report on Thursday, January 18th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Agios Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $87.00.

In other news, CEO David P. Schenkein sold 53,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $73.16, for a total transaction of $3,877,480.00. Following the transaction, the chief executive officer now owns 53,000 shares of the company’s stock, valued at $3,877,480. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Corp /De/ Celgene purchased 851,154 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, January 23rd. The shares were bought at an average cost of $67.00 per share, for a total transaction of $57,027,318.00. Following the transaction, the insider now directly owns 1,374,599 shares of the company’s stock, valued at approximately $92,098,133. The disclosure for this purchase can be found here. Insiders have sold 210,880 shares of company stock worth $16,368,948 in the last ninety days. Corporate insiders own 5.43% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Agios Pharmaceuticals by 41.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 762 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $160,000. Bank of Montreal Can lifted its position in shares of Agios Pharmaceuticals by 74.8% during the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 1,520 shares during the last quarter. Macquarie Group Ltd. bought a new position in shares of Agios Pharmaceuticals during the third quarter worth about $245,000. Finally, Xact Kapitalforvaltning AB bought a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $259,000. 82.41% of the stock is currently owned by institutional investors and hedge funds.

Shares of Agios Pharmaceuticals stock opened at $87.33 on Friday. The firm has a market cap of $4,834.36, a P/E ratio of -12.94 and a beta of 1.98. Agios Pharmaceuticals has a twelve month low of $45.11 and a twelve month high of $89.33.

TRADEMARK VIOLATION WARNING: This report was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://dakotafinancialnews.com/2018/04/14/zacks-brokerages-expect-agios-pharmaceuticals-agio-will-announce-quarterly-sales-of-13-59-million.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply